Targeting IGF-1R: throwing out the baby with the bathwater?
2011

Targeting IGF-1R: throwing out the baby with the bathwater?

Editorial Evidence: low

Author Information

Author(s): Basu B, Olmos D, de Bono J S

Primary Institution: The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research

Conclusion

Pre-treatment free IGF-1 concentration is a predictive biomarker of clinical benefit from figitumumab at 20 mg/kg but not at 10 mg/kg in NSCLC.

Supporting Evidence

  • Low IGF-1 levels are associated with prolonged survival in NSCLC.
  • Pre-treatment fIGF-1 was not predictive of PFS in patients receiving chemotherapy alone.
  • Figitumumab has shown anti-tumour activity in metastatic Ewing's sarcoma.

Takeaway

This study looks at a blood marker that might help doctors know which lung cancer patients will benefit from a specific treatment. It found that one level of this marker is helpful, but another level is not.

Limitations

The analysis is complicated by the small sample size and biological heterogeneity of patients, and the use of one-sided tests limits statistical power.

Participant Demographics

The study mentions that higher baseline fIGF-1 is present in females and patients with adenocarcinoma.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6606023

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication